Edwards Lifesciences (EW)Officer sold ~$50K

~$50K

Approx. value · 583 sh @ $86.01

18K

Holds after · shares reported

Traded

Dec 8, 2025

Filed

Dec 8, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 17, 20255% stakeBlackRock, Inc. reported a passive stake (13G) of 7.5%
2. Oct 21, 2025FDAFDA device clearance: HemoSphere Stream Module
3. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
4. Oct 30, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 30, 2025, Scott Ullem, the Chief Financial Officer of Edwards Lifesciences Corporation, a Delaware corporation (the “Corporation”), informed the Corporation of his decision to transition from his role by mid-year 2026.”
5. Nov 10, 2025Insider · 2 peopleInsiders: 3 sales (~$1.2M)
6. Nov 19, 2025CongressDisclosed sale of EW — reported range $1,001 - $15,000
7. Dec 8, 2025 · this disclosureInsiderOfficer sold ~$50K of EW shares in the open market

What came next

1. Dec 8, 2025InsiderCEO sold ~$1.83M of EW shares in the open market
2. Dec 9, 2025InsiderCFO sold ~$650K of EW shares in the open market
3. Dec 10, 2025Insider · 2 peopleInsiders: 2 sales (~$1.3M)
4. Dec 11, 2025InsiderOfficer sold ~$169K of EW shares in the open market
5. Dec 12, 2025Insider · 3 peopleInsiders: 4 sales (~$1.3M)
6. Dec 18, 2025FDAFDA device clearance: HemoSphere Alta Advanced Monitoring Platform (ALTAALL1; ALTACR1; ALTASR1)
7. Dec 22, 2025FDAFDA device approval: SAPIEN M3 Transcatheter Mitral Valve Replacement System
8. Jan 6, 2026Insider · 1 personInsiders: 2 sales (~$971K)
9. Jan 9, 2026InsiderOfficer sold ~$87K of EW shares in the open market
10. Feb 10, 2026Company filing · Form 8-K · ResultsReported its results
11. Feb 12, 2026Insider · 1 personInsiders: 2 sales (~$1.7M)
12. Feb 24, 2026FDAFDA device clearance: HemoSphere Nano Monitor (HSNANO1)
13. Feb 25, 2026InsiderOfficer sold ~$2.01M of EW shares in the open market
14. Mar 2, 2026InsiderOfficer sold ~$974K of EW shares in the open market
15. Mar 11, 2026Insider · 2 peopleInsiders: 3 sales (~$1.2M)
16. Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
17. Mar 27, 2026FDARecall: Edwards EVOQUE tricuspid delivery system REF:9850TDS Sterile EO
18. Apr 2, 2026Insider · 1 personInsiders: 2 sales (~$1.8M)
19. Apr 6, 2026InsiderOfficer sold ~$83K of EW shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Edwards Lifesciences

For Edwards Lifesciences, OQRO holds 11 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 21 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EW page.

Other recent filings by Wayne Markowitz, CVP, JAPAC

• SEC Form 4 at Edwards Lifesciences (EW)Aug 26, 2026
• SEC Form 4 at Edwards Lifesciences (EW)Jul 30, 2026
• SEC Form 4 at Edwards Lifesciences (EW)Jul 28, 2026
• SEC Form 4 at Edwards Lifesciences (EW)May 12, 2026
• SEC Form 4 at Edwards Lifesciences (EW)May 9, 2025

The full history of Wayne Markowitz, CVP, JAPAC is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Edwards Lifesciences

• SEC Form 4Oct 8, 2026
• SEC Form 4Sep 11, 2026
• SEC Form 4Aug 31, 2026
• SEC Form 4Aug 28, 2026
• SEC Form 4Aug 26, 2026
• SEC Form 4Aug 26, 2026

Everything OQRO holds on this company is on its EW page.